Annovis Bio, Inc. Common Stock (ANVS)

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer’s and Parkinson’s diseases, reported third-quarter 2026 corporate updates, highlighting progress in its pivotal Phase 3 DUET-AD trial and preparations for a planned New Drug Application (“NDA”). The fully enrolled trial includes 862 patients with early Alzheimer’s disease and features two prespecified efficacy readouts at six and 18 months to evaluate symptomatic and disease-modifying effects, respectively. The company expects topline results from the six-month treatment period in March 2027 and plans to begin transitioning eligible patients into its Alzheimer’s open-label extension study by the end of November 2026.

MALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and reported financial results for the third quarter ended September 30, 2026.

MALVERN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,780,831, titled “Solid Forms of Posiphen D-Tartrate.”

MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 19 million common shares, pre-funded warrants to purchase up to 2 million shares and accompanying warrants to purchase up to 21 million shares. The combined offering price is $1 per common share and accompanying warrant, or $0.9999 per pre-funded warrant and accompanying warrant. The accompanying warrants have an exercise price of $1 per share and expire five years after issuance. Annovis expects gross proceeds of approximately $21 million, excluding potential proceeds from warrant exercises and before deducting offering expenses. The offering is expected to close on or about Nov. 6, 2026, subject to customary closing conditions.

Annovis Bio (NYSE: ANVS) a Phase 3 clinical-stage biotechnology company, announced a proposed underwritten public offering of common stock or pre-funded warrants in lieu of common stock, together with accompanying warrants to purchase common stock. The securities will be issued separately but must be purchased together. Canaccord Genuity is acting as sole bookrunner. Annovis intends to use the net proceeds to advance clinical development of its investigational oral therapy buntanetap for Alzheimer’s disease and Parkinson’s disease, as well as for working capital and general corporate purposes. The proposed offering remains subject to market and other conditions, with no assurance regarding its completion, size or terms.

MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of (i) 19,000,000 shares of its common stock and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares of its common stock, and (ii) accompanying warrants to purchase up to 21,000,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.00, and the combined offering price of each Pre-Funded Warrant to purchase one share of common stock and accompanying warrant is $0.9999, which equals the combined offering price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each Pre-Funded Warrant. Each accompanying warrant will be exercisable for one share of common stock at an exercise price of $1.00 per share of common stock, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The Pre-Funded Warrants will be exercisable immediately upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer’s and Parkinson’s diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis’ clinical programs and upcoming milestones.

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

Annovis Bio (NYSE: ANVS) announced plans to deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference, scheduled for Nov. 16-19, 2026, in Boston. The presentations will highlight the company’s investigational oral therapy buntanetap, including its mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer’s disease and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer’s drug candidates.

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Annovis Bio (NYSE: ANVS) announced a collaboration with Weave Bio to support preparation of the planned New Drug Application (“NDA”) for buntanetap, its investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Annovis will use the Weave AI platform to draft, review and manage NDA documents, while its regulatory and clinical teams will retain responsibility for content, verification and final approval of all documents submitted to the U.S. Food and Drug Administration (“FDA”).

MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.

Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced it will host a corporate update webinar Sept. 2, 2026, at 4 p.m. EDT, followed by a live question-and-answer session. Founder, President and CEO Maria Maccecchini, Ph.D., will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027. Annovis also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its PD open-label study is underway and discussions continue regarding initiation of a Parkinson’s disease dementia program.

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.